Hollie Franklin, Author at Drugs in Context

Neurological features of COVID-19 and their treatment: a review

Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

Article Type

Review

Published

11 Jun 2020

This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment
approaches.

Nail enthesis ultrasound and automated software-guided assessment of bilateral common carotid intima–media thickness in psoriasis and psoriatic arthritis: is there a correlation with clinical and laboratory findings?

José Alexandre Mendonça PhD, Lucas Nogueira Pansani MD, Mateus Basso Mimoto MD, Igor Tadeu Garcia Ferreira MD, Fernanda Bertucci Sanches MD, Thais de Campos Ferreira Pinto MD, Vania Aparecida Leandro-Merhi PhD, José Luis Braga de Aquino PhD

Article Type

Original Research

Published

03 Jun 2020

The objective of this study was to detect and correlate the changes that indicate the inflammatory and atherosclerotic process in psoriasis and psoriatic arthritis patients, using nail ultrasound and carotid artery intima–media thickness radiofrequency software.

Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Alberto Romano MD, Palma Maurizi MD, Stefano Mastrangelo MD, Giorgio Attinà MD

Article Type

Review

Published

02 Jun 2020

The article reviews the results
derived from the combination use of TMZ and oral VP-16 to treat malignant brain tumors

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD

Article Type

Editorial

Published

26 May 2020

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.

Antidepressant efficacy and side effect burden: an updated guide for clinicians

Tatum Kutzer DO, Michelle Dick MD, Trevor Scudamore MD, Mark Wiener MD, Thomas Schwartz MD

Article Type

Review

Published

26 May 2020

This article serves to provide clinicians with updated information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts.